35409 Utilization and trends of select FDA indicated cutaneous T-cell lymphoma prescriptions among Medicare Part D patients: 2013-2019

Abstract

Background: Cutaneous T-cell lymphoma (CTCL) is an indolent malignancy of T-cells with various cutaneous presentations. Limited data exist on national prescription patterns for select FDA indicated drugs such as mechlorethamine, bexarotene, vorinostat and romidepsin. The goal of this study was to assess these patterns. Design: A retrospective analysis was conducted using the Medicare Part D Prescriber datasets from 2013-2019. Mechlorethamine, bexarotene, vorinostat and romidepsin data were extracted. Yearly claims per 100,000 beneficiaries, total drug costs, and total prescribers were recorded. Average annual growth rate (AAGR) was calculated and trend significance was determined through a linear regression model. Summary: From 2013-2019, AAGR for claims per 100k beneficiaries increased for mechlorethamine (99%) and romidepsin (11.5%), but decreased for bexarotene (-1.3%) and vorinostat (-16.4%). However, no statistically significant increased or decreased trend was seen for total drug costs or total prescribers for any of the assessed CTCL drugs. Conclusion: Mechlorethamine and romidepsin claims increased while bexarotene and vorinostat claims decreased over the years. Total costs and prescribers have remained stable with no significant trend for all examined drugs. Future studies are warranted to assess whether these drugs may lose preference over newer CTCL drugs such as brentuximab vedotin or mogamulizumab as more data becomes available.